Sign in to view content

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)

Chirag D. Jhaveri, MD, FASRS

Video
Published 2021

Related

Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more